$2.58T
Total marketcap
$168.73B
Total volume
BTC 50.03%     ETH 15.83%
Dominance

Xencor XNCR Stock

22.25 USD {{ price }} -3.637939% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
1.36B USD
LOW - HIGH [24H]
22.07 - 23.8 USD
VOLUME [24H]
505.07K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.08 USD

Xencor Price Chart

Xencor XNCR Financial and Trading Overview

Xencor stock price 22.25 USD
Previous Close 26.54 USD
Open 26.43 USD
Bid 0 USD x 1100
Ask 0 USD x 1100
Day's Range 26.11 - 26.69 USD
52 Week Range 21.66 - 38.2 USD
Volume 240.28K USD
Avg. Volume 291.42K USD
Market Cap 1.6B USD
Beta (5Y Monthly) 0.763028
PE Ratio (TTM) N/A
EPS (TTM) -2.08 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 43 USD

XNCR Valuation Measures

Enterprise Value 1.07B USD
Trailing P/E N/A
Forward P/E -9.131034
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 16.310184
Price/Book (mrq) 2.339016
Enterprise Value/Revenue 10.954
Enterprise Value/EBITDA -6.801

Trading Information

Xencor Stock Price History

Beta (5Y Monthly) 0.763028
52-Week Change 15.03%
S&P500 52-Week Change 20.43%
52 Week High 38.2 USD
52 Week Low 21.66 USD
50-Day Moving Average 27.51 USD
200-Day Moving Average 28.56 USD

XNCR Share Statistics

Avg. Volume (3 month) 291.42K USD
Avg. Daily Volume (10-Days) 291.48K USD
Shares Outstanding 60.39M
Float 54.71M
Short Ratio 19.05
% Held by Insiders 0.86%
% Held by Institutions 105.25%
Shares Short 5.4M
Short % of Float 14.77%
Short % of Shares Outstanding 8.94%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -142.31%
Operating Margin (ttm) -170.11%
Gross Margin -120.49%
EBITDA Margin -161.074%

Management Effectiveness

Return on Assets (ttm) -12.55%
Return on Equity (ttm) -19.29%

Income Statement

Revenue (ttm) 98.05M USD
Revenue Per Share (ttm) 1.64 USD
Quarterly Revenue Growth (yoy) -77.79%
Gross Profit (ttm) -34984000 USD
EBITDA -157928000 USD
Net Income Avi to Common (ttm) -139538000 USD
Diluted EPS (ttm) -2.29
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 588.02M USD
Total Cash Per Share (mrq) 9.74 USD
Total Debt (mrq) 59.24M USD
Total Debt/Equity (mrq) 8.67 USD
Current Ratio (mrq) 9.684
Book Value Per Share (mrq) 11.321

Cash Flow Statement

Operating Cash Flow (ttm) -11944000 USD
Levered Free Cash Flow (ttm) -21431250 USD

Profile of Xencor

Country United States
State CA
City Monrovia
Address 111 West Lemon Avenue
ZIP 91016
Phone 626 305 5900
Website https://www.xencor.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 281

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Q&A For Xencor Stock

What is a current XNCR stock price?

Xencor XNCR stock price today per share is 22.25 USD.

How to purchase Xencor stock?

You can buy XNCR shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Xencor?

The stock symbol or ticker of Xencor is XNCR.

Which industry does the Xencor company belong to?

The Xencor industry is Biotechnology.

How many shares does Xencor have in circulation?

The max supply of Xencor shares is 61.12M.

What is Xencor Price to Earnings Ratio (PE Ratio)?

Xencor PE Ratio is now.

What was Xencor earnings per share over the trailing 12 months (TTM)?

Xencor EPS is -2.08 USD over the trailing 12 months.

Which sector does the Xencor company belong to?

The Xencor sector is Healthcare.

Xencor XNCR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD